Stay updated with breaking news from Ymphoblastic. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
UCART22 is currently the most advanced allogeneic CAR T-cell product in development for relapsed or refractory B-cell acute lymphoblastic leukemia The BALLI-01 study is actively enrolling patients. | April 11, 2023 ....
A new study shows a diet high in vitamin A or its analogues might assist adolescents and young adults with Acute Lymphoblastic Leukaemia (ALL) in lowering their risk of painful pancreatic inflammation during chemotherapy. ....
A diet high in vitamin A or its analogues may assist children and teenagers with acute lymphoblastic leukaemia (ALL) lower their likelihood of experiencing uncomfortable pancreatic inflammation during chemotherapy. ....
In Three-Year Follow-up in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia, Tecartus Shows High Rates of Durable Response (CR+CRi 71%) and a Median Overall Survival of 26 Months ....
In Three-Year Follow-up in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia, Tecartus Shows High Rates of Durable Response and a Median Overall Survival of 26 Months . | February 9, 2023 ....